JA Johnson

2.5k total citations · 2 hit papers
23 papers, 1.7k citations indexed

About

JA Johnson is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Pharmacology. According to data from OpenAlex, JA Johnson has authored 23 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Endocrinology, Diabetes and Metabolism, 7 papers in Cardiology and Cardiovascular Medicine and 6 papers in Pharmacology. Recurrent topics in JA Johnson's work include Hormonal Regulation and Hypertension (8 papers), Pharmacogenetics and Drug Metabolism (6 papers) and Renin-Angiotensin System Studies (4 papers). JA Johnson is often cited by papers focused on Hormonal Regulation and Hypertension (8 papers), Pharmacogenetics and Drug Metabolism (6 papers) and Renin-Angiotensin System Studies (4 papers). JA Johnson collaborates with scholars based in United States, Taiwan and United Kingdom. JA Johnson's co-authors include Brian F. Gage, Stephen B. Liggett, HL McLeod, Gloria R. Grice, P. M. Ridker, Petra Lenzini, DL Veenstra, Steven G. E. Marsh, Taimour Langaee and Elena Deych and has published in prestigious journals such as The Lancet Infectious Diseases, Clinical Pharmacology & Therapeutics and British Journal of Clinical Pharmacology.

In The Last Decade

JA Johnson

23 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin

2008 595 citations Brian F. Gage, Charles Eby et al. Clinical Pharmacology & Therapeutics profile →
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update

2017 435 citations JA Johnson, Li Gong et al. Clinical Pharmacology & Therapeutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
JA Johnson United States	17	940	394	367	301	197	23	1.7k
Yoseph Caraco Israel	27	946 1.0×	270 0.7×	233 0.6×	432 1.4×	296 1.5×	102	2.3k
Christina L. Aquilante United States	26	829 0.9×	248 0.6×	371 1.0×	349 1.2×	468 2.4×	87	2.3k
P. M. Ridker United States	8	516 0.5×	344 0.9×	284 0.8×	168 0.6×	78 0.4×	9	1.4k
John A. Pieper United States	25	951 1.0×	283 0.7×	281 0.8×	256 0.9×	290 1.5×	65	1.9k
Shitalben Patel United States	22	677 0.7×	170 0.4×	266 0.7×	222 0.7×	126 0.6×	66	1.5k
Daniel Kurnik Israel	25	423 0.5×	395 1.0×	295 0.8×	296 1.0×	191 1.0×	86	1.9k
Hong‐Guang Xie United States	22	863 0.9×	412 1.0×	284 0.8×	626 2.1×	249 1.3×	40	2.3k
Carlos A. Dujovne United States	34	354 0.4×	506 1.3×	1.1k 3.0×	452 1.5×	149 0.8×	108	3.7k
Aleksi Tornio Finland	25	883 0.9×	376 1.0×	281 0.8×	295 1.0×	276 1.4×	68	1.9k
H.H.W. Thijssen Netherlands	26	658 0.7×	220 0.6×	405 1.1×	301 1.0×	83 0.4×	97	2.4k

Countries citing papers authored by JA Johnson

Since Specialization

Citations

This map shows the geographic impact of JA Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by JA Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites JA Johnson more than expected).

Fields of papers citing papers by JA Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by JA Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by JA Johnson. The network helps show where JA Johnson may publish in the future.

Co-authorship network of co-authors of JA Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of JA Johnson. A scholar is included among the top collaborators of JA Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with JA Johnson. JA Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Johnson, JA, Li Gong, Michelle Whirl‐Carrillo, et al.. (2017). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update. Clinical Pharmacology & Therapeutics. 102(3). 397–404. 435 indexed citations breakdown →

Chang, Soon Woong, et al.. (2016). Melatonin Pathway and Atenolol‐Related Glucose Dysregulation: Is There a Correlation?. Clinical and Translational Science. 9(2). 114–122. 11 indexed citations

Lima, S.M., Felipe Proenço de Oliveira, Lisa Wilson, et al.. (2016). Impact of GGCX, STX1B and FPGS Polymorphisms on Warfarin Dose Requirements in European‐Americans and Egyptians. Clinical and Translational Science. 9(1). 36–42. 7 indexed citations

Rotroff, Daniel M., Hongjie Zhu, Alison A. Motsinger‐Reif, et al.. (2015). Pharmacometabolomic Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response Phenotypes. CPT Pharmacometrics & Systems Pharmacology. 4(11). 669–679. 30 indexed citations

Johnson, JA & Stephen B. Liggett. (2011). Cardiovascular Pharmacogenomics of Adrenergic Receptor Signaling: Clinical Implications and Future Directions. Clinical Pharmacology & Therapeutics. 89(3). 366–378. 91 indexed citations

Gage, Brian F., Charles Eby, JA Johnson, et al.. (2008). Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin. Clinical Pharmacology & Therapeutics. 84(3). 326–331. 595 indexed citations breakdown →

Gong, Yan, Daqing Wang, Juhee Shin, et al.. (2008). Promoter Polymorphisms in ACE (Angiotensin I–Converting Enzyme) Associated With Clinical Outcomes in Hypertension. Clinical Pharmacology & Therapeutics. 85(1). 36–44. 27 indexed citations

Gong, Yan, et al.. (2008). β-Adrenergic Receptor Gene Polymorphisms and β-Blocker Treatment Outcomes in Hypertension. Clinical Pharmacology & Therapeutics. 84(6). 715–721. 98 indexed citations

Smith, David L., et al.. (2003). Assessing risks for a pre-emergent pathogen: virginiamycin use and the emergence of streptogramin resistance in Enterococcus faecium. The Lancet Infectious Diseases. 3(4). 241–249. 62 indexed citations

10.

Johnson, JA, et al.. (1995). Influence of metabolites on protein binding of verapamil enantiomers.. British Journal of Clinical Pharmacology. 39(5). 536–538. 5 indexed citations

11.

Johnson, JA. (1991). Diastolic dysfunction in congestive heart failure.. PubMed. 10(11). 850–61. 2 indexed citations

12.

Gotshall, R. W., et al.. (1973). Effects of renal denervation on renin release in sodium-depleted dogs. American Journal of Physiology-Legacy Content. 225(2). 344–349. 22 indexed citations

13.

Johnson, JA, et al.. (1971). Effects of hemorrhage and chronic sodium depletion on hepatic clearance of renin. American Journal of Physiology-Legacy Content. 220(6). 1677–1682. 25 indexed citations

14.

Davis, Jo Ann, et al.. (1970). Chronic experimental left heart failure in the dog. American Journal of Physiology-Legacy Content. 219(2). 474–480. 2 indexed citations

15.

Schneider, EG, et al.. (1970). Lack of evidence for a hepatic osmoreceptor mechanism in conscious dogs. American Journal of Physiology-Legacy Content. 218(1). 42–45. 36 indexed citations

16.

Johnson, JA, et al.. (1970). Effects of estrogens and progesterone on electrolyte balances in normal dogs. American Journal of Physiology-Legacy Content. 219(6). 1691–1697. 26 indexed citations

17.

Wangensteen, O. Douglas, et al.. (1969). Permeability of the mammalian blood-gas barrier and its components. American Journal of Physiology-Legacy Content. 216(4). 719–727. 62 indexed citations

18.

Johnson, JA, et al.. (1969). Left atrial pressure, plasma osmolality, and ADH levels in the unanesthetized ewe. American Journal of Physiology-Legacy Content. 217(6). 1672–1680. 35 indexed citations

19.

Johnson, JA, et al.. (1967). Permeability of rabbit heart capillaries to nonelectrolytes. American Journal of Physiology-Legacy Content. 213(1). 87–93. 36 indexed citations

20.

Johnson, JA. (1966). Capillary permeability, extracellular space estimation, and lymph flow. American Journal of Physiology-Legacy Content. 211(5). 1261–1263. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact